Avanafil
From Wikipedia, the free encyclopedia
 |
|
|
Avanafil
|
|
| Systematic (IUPAC) name | |
| 4-[(3-Chloro-4-methoxybenzyl)amino]-2-
[2-(hydroxymethyl)-1-pyrrolidinyl]-N- (2-pyrimidinylmethyl)-5-pyrimidinecarboxamide |
|
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C23H26ClN7O3 |
| Mol. mass | 483.951 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Avanafil is a PDE5 inhibitor being developed for erectile dysfunction.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||
